ExodusPoint Capital Management LP Takes Position in Evolus, Inc. (NASDAQ:EOLS)

ExodusPoint Capital Management LP bought a new position in Evolus, Inc. (NASDAQ:EOLS) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 13,525 shares of the company’s stock, valued at approximately $149,000.

Other large investors have also added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in shares of Evolus by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 1,214,590 shares of the company’s stock worth $13,412,000 after buying an additional 3,969 shares during the last quarter. Schroder Investment Management Group lifted its holdings in Evolus by 2.5% in the fourth quarter. Schroder Investment Management Group now owns 1,040,440 shares of the company’s stock valued at $11,330,000 after acquiring an additional 25,480 shares during the period. Lord Abbett & CO. LLC boosted its position in Evolus by 23.4% in the third quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock worth $16,126,000 after purchasing an additional 188,685 shares during the last quarter. Rice Hall James & Associates LLC grew its stake in shares of Evolus by 4.8% during the 4th quarter. Rice Hall James & Associates LLC now owns 948,281 shares of the company’s stock valued at $10,469,000 after purchasing an additional 43,381 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Evolus by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 421,481 shares of the company’s stock valued at $4,653,000 after purchasing an additional 2,905 shares during the last quarter. Institutional investors own 90.69% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on EOLS. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price objective on shares of Evolus in a report on Wednesday, April 9th. Barclays boosted their price objective on shares of Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $27.00 target price on shares of Evolus in a report on Thursday, April 10th.

Insider Activity at Evolus

In related news, insider Rui Avelar sold 27,904 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $370,007.04. Following the transaction, the insider now directly owns 362,467 shares of the company’s stock, valued at approximately $4,806,312.42. The trade was a 7.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Karah Herdman Parschauer sold 12,888 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total transaction of $167,415.12. Following the sale, the director now directly owns 32,183 shares of the company’s stock, valued at approximately $418,057.17. This trade represents a 28.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 60,575 shares of company stock worth $794,369. 6.10% of the stock is owned by corporate insiders.

Evolus Price Performance

Shares of NASDAQ:EOLS opened at $10.27 on Tuesday. The firm’s 50 day simple moving average is $12.85 and its two-hundred day simple moving average is $13.27. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The company has a market capitalization of $653.04 million, a P/E ratio of -11.29 and a beta of 0.97. Evolus, Inc. has a 1-year low of $8.67 and a 1-year high of $17.82.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.